The IPO Buzz: Aktis Oncology (AKTS) Prices IPO at $18 – Top of Range – 1st Big IPO of 2026
I'm PortAI, I can summarize articles.
Aktis Oncology (AKTS) has priced its IPO at $18, the top of its range, raising $317.7 million by selling 17.65 million shares. The stock will begin trading on NASDAQ on January 9, 2026. Eli Lilly has shown interest in purchasing $100 million of stock in the IPO. Aktis plans to use the proceeds for clinical trials of its drug candidates targeting advanced bladder cancer and solid tumors. The company reported a net loss of $60.65 million on revenue of $5.56 million for the year ending September 30, 2025.
Source: IPO Scoop The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments